Ernexa director granted options on 5,943 shares

Ernexa Therapeutics Inc. (ERNA) reported that director William A. Wexler received a grant of stock options for 5,943 shares of common stock.

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) reported that director William A. Wexler received a grant of stock options for 5,943 shares of common stock. The options have an exercise price of $4.57 per share and expire on August 31, 2036. Following this grant, Wexler holds 5,943 stock options directly. Vesting is time-based: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.

Insider Trade Summary

Grant/Award: 5,943 shares

Grant/Award 1 txn

Insider Wexler William A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy) F1	5,943	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 5,943 contracts (Direct)

Footnotes (1)

1. F1. Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

Key Figures

Stock options granted: 5,943 shares Exercise price: $4.57 per share Expiration date: August 31, 2036 +3 more

6 metrics

Stock options granted 5,943 shares Number of stock option shares granted to William A. Wexler on 2026-08-31

Exercise price $4.57 per share Conversion or exercise price of the stock option granted on 2026-08-31

Expiration date August 31, 2036 Expiration date of the granted stock option

Total options held after transaction 5,943 options Total derivative shares following the reported grant for William A. Wexler

Initial vesting portion One-third of 5,943 shares Vests on the first anniversary of the grant date, subject to continued service

Remaining vesting installments 24 monthly installments Remaining option shares vest in 24 substantially equal monthly installments after first anniversary

Key Terms

Stock Option (Right to buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.5700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-08-31"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"shares underlying the stock option will vest in 24 substantially equal monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director William A. Wexler report in this Form 4 for ERNA?

He reported a grant of stock options for 5,943 shares of Ernexa Therapeutics Inc. common stock, with an exercise price of $4.57 per share and an expiration date of August 31, 2036.

Is the Form 4 transaction for ERNA a purchase or a grant of options?

The Form 4 discloses a grant/award acquisition of a stock option, not an open-market purchase or sale. The transaction code is A, indicating a grant or other acquisition of derivative securities.

How many ERNA shares underlie the stock options granted to William A. Wexler?

The stock option grant covers 5,943 underlying shares of Ernexa Therapeutics Inc. common stock. The Form 4 states 5,943.0000 underlying security shares for the option award.

What is the vesting schedule of William A. Wexler’s ERNA stock options?

The options vest based on continued service: one-third of the underlying shares vest on the first anniversary of the grant date, and the remaining shares vest in 24 substantially equal monthly installments thereafter.

What is the exercise price and expiration date of the ERNA options granted?

The options have an exercise price of $4.57 per share and an expiration date of August 31, 2036, as disclosed in the Form 4 transaction details.

How many ERNA stock options does William A. Wexler hold after this transaction?

After this grant, William A. Wexler directly holds 5,943 stock options of Ernexa Therapeutics Inc., according to the Form 4’s “total shares following transaction” field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 09:48 PM EDT Accepted by SEC EDGAR 09/01/2026 - 09:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wexler William A.

(Last) (First) (Middle)

C/O ERNEXA THERAPEUTICS INC.

1035 CAMBRIDGE STREET, SUITE 18A

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ernexa Therapeutics Inc. [ ERNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$4.57	08/31/2026		A		5,943		(1)	08/31/2036	Common Stock	5,943	$0	5,943	D

Explanation of Responses:

1. Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

	/s/ William Wexler	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)